PuSH - Publication Server of Helmholtz Zentrum München

Lugar, M.* ; Eugster, A.* ; Achenbach, P. ; von dem Berge, T.* ; Berner, R.* ; Besser, R.E.J.* ; Casteels, K.* ; Elding Larsson, H.* ; Gemulla, G.* ; Kordonouri, O.* ; Lindner, A.* ; Lundgren, M.* ; Müller, D.* ; Oltarzewski, M.* ; Rochtus, A.* ; Scholz, M. ; Szypowska, A.* ; Todd, J.A.* ; Ziegler, A.-G. ; Bonifacio, E.

SARS-CoV-2 infection and development of islet autoimmunity in early childhood.

JAMA 330, 1151-1160 (2023)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Importance: The incidence of diabetes in childhood has increased during the COVID-19 pandemic. Elucidating whether SARS-CoV-2 infection is associated with islet autoimmunity, which precedes type 1 diabetes onset, is relevant to disease etiology and future childhood diabetes trends. Objective: To determine whether there is a temporal relationship between SARS-CoV-2 infection and the development of islet autoimmunity in early childhood. Design, Setting, and Participants: Between February 2018 and March 2021, the Primary Oral Insulin Trial, a European multicenter study, enrolled 1050 infants (517 girls) aged 4 to 7 months with a more than 10% genetically defined risk of type 1 diabetes. Children were followed up through September 2022. Exposure: SARS-CoV-2 infection identified by SARS-CoV-2 antibody development in follow-up visits conducted at 2- to 6-month intervals until age 2 years from April 2018 through June 2022. Main Outcomes and Measures: The development of multiple (≥2) islet autoantibodies in follow-up in consecutive samples or single islet antibodies and type 1 diabetes. Antibody incidence rates and risk of developing islet autoantibodies were analyzed. Results: Consent was obtained for 885 (441 girls) children who were included in follow-up antibody measurements from age 6 months. SARS-CoV-2 antibodies developed in 170 children at a median age of 18 months (range, 6-25 months). Islet autoantibodies developed in 60 children. Six of these children tested positive for islet autoantibodies at the same time as they tested positive for SARS-CoV-2 antibodies and 6 at the visit after having tested positive for SARS-CoV-2 antibodies. The sex-, age-, and country-adjusted hazard ratio for developing islet autoantibodies when the children tested positive for SARS-CoV-2 antibodies was 3.5 (95% CI, 1.6-7.7; P =.002). The incidence rate of islet autoantibodies was 3.5 (95% CI, 2.2-5.1) per 100 person-years in children without SARS-CoV-2 antibodies and 7.8 (95% CI, 5.3-19.0) per 100 person-years in children with SARS-CoV-2 antibodies (P =.02). Islet autoantibody risk in children with SARS-CoV-2 antibodies was associated with younger age (<18 months) of SARS-CoV-2 antibody development (HR, 5.3; 95% CI, 1.5-18.3; P =.009). Conclusion and relevance: In young children with high genetic risk of type 1 diabetes, SARS-CoV-2 infection was temporally associated with the development of islet autoantibodies..
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Autoantibody Assays; Genetic Risk; Type-1; Children; Progression; Prediction
ISSN (print) / ISBN 0098-7484
e-ISSN 1538-3598
Journal JAMA: Journal of the American Medical Association
Quellenangaben Volume: 330, Issue: 12, Pages: 1151-1160 Article Number: , Supplement: ,
Publisher American Medical Association
Publishing Place 330 N Wabash Ave, Ste 39300, Chicago, Il 60611-5885 Usa
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)
Institute of Diabetes Research Type 1 (IDF)
Institute of Diabetes and Obesity (IDO)
Grants Wellcome Trust